Status:
COMPLETED
Neovac 2 Burkina Faso: Impact of the Integration of Hepatitis B Birth Dose Vaccine Into the Infant Immunization Schedule
Lead Sponsor:
Institut Pasteur
Collaborating Sponsors:
Agence de Médecine Préventive, France
Centre Muraz
Conditions:
Hepatitis B
Eligibility:
FEMALE
15-55 years
Phase:
NA
Brief Summary
Hepatitis B virus (HBV) infection is an important global health problem, and the WHO adopted a strategy to eliminate HBV infection as a public health threat by the year 2030. In order to eliminate, it...
Detailed Description
The study combines mixed methods to achieve its aim of evaluating the impact of the introduction of birth dose hepatitis B vaccine into the infant immunisation program in Burkina Faso. It is composed ...
Eligibility Criteria
Inclusion
- Pregnant woman
- Living in the study area
- Visited study health centre for the antenatal care or child delivery
- Provided a written informed consent
Exclusion
- Miscarriage, abortion, stillborn, neonatal defect incompatible with life
- Any mother or child condition incompatible with the research activities
Key Trial Info
Start Date :
October 19 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 15 2023
Estimated Enrollment :
10000 Patients enrolled
Trial Details
Trial ID
NCT04029454
Start Date
October 19 2020
End Date
December 15 2023
Last Update
December 19 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
District sanitaire de Dafra
Bobo-Dioulasso, Dafra, Burkina Faso
2
District sanitaire de Do
Bobo-Dioulasso, Do, Burkina Faso